Oberlin-based Synapse Biomedical recently secured U.S. Food and Drug Administration premarket approval for its diaphragm pacing system for use in patients with spinal cord injuries (SCI) who rely on mechanical ventilation.
/PRNewswire/ Synapse Biomedical, Inc. announced today that the FDA has granted premarket approval (PMA) of the NeuRx® Diaphragm Pacing System (NeuRx DPS®).